Qurgen is a biotechnology company that focuses on the development of efficient protein in vitro and in vivo Cell and tissue reprogramming technology. It features the breakthrough protein targeted transport and efficient in vitro and in vivo protein-induced stem cells and other patented technologies. The company was founded in 2016 and headquartered in Iowa, United States.

Higher Steaks LTD engages in production of meat and poultry meat products. The company was founded on March 8, 2018 and is headquartered in Bristol, the United Kingdom.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type. The platforms can be used to enhance existing stem-cell forward programming methods, or bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease. Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications.

Diversa Corporation is an industrial biotechnology company that develops high performance enzymes. It extracts microbial DNA directly from collected samples to avoid the often impossible task of growing microbes in the laboratory. It mines its collection of microbial genes, numbering in the billions, using high-throughput screening technologies designed to identify unique enzymes as product candidates. Diversa Corporation develops enzymes that are environmentally friendly and more cost-effective for industries such as the global food and fuel markets. It has developed enzymes  to meet the specific needs of companies in various markets, including grain processing, bio fuels, animal health and nutrition and other industries.

The Eli and Edythe L. Broad Institute of MIT and Harvard (/ˈbroʊd/), often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and is partners with Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

AngioGenex, Inc. operates as a biopharmaceutical company, which engages in developing and commercializing novel platform of anti-proliferative drugs for the treatment of cancer and macular degeneration. The company was founded by Michael M. Strage and Robert Benezra in March 1999 and is headquartered in New York, NY.

Research Corporation Technologies, Inc. provides investment related services. It operates as technology development company that typically invests in new technology platforms in life sciences, healthcare technology, biomedical, preclinical and clinical-stage therapeutics, devices, drugs, and diagnostics, medical devices, and biotech tools for gene expression and protein production with medical devices. The company was founded in 1987 and is headquartered in Tucson, AZ.

Hubei Huazhong Pharmaceutical Co. Ltd. (doing business as Huazhong Pharmaceutical Co. Ltd.) is a company headquartered in Xiangfan, China and ultimately controlled by the Government of China, specializing in pharmaceutical preparations.

Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery.

Solexa engages in developing and commercializing genetic analysis technologies primarily in the United States and the United Kingdom. The company is developing and preparing Solexa Genome Analysis System, which performs DNA sequencing based on its proprietary reversible terminator Sequencing-by-Synthesis, chemistry, and Clonal Single Molecule Array technology. Its platform is designed to support a range of analyses, including whole genome resequencing, gene expression analysis, and small RNA analysis.

Shanghai Lai Shi Blood Products Co., Ltd. was established in 1988. It was listed on the Shenzhen Stock Exchange in 2008 (stock code: 002252) and is a well-known blood products company in Asia. Since its establishment 30 years ago, the company has been adhering to the quality policy of “safe, high quality and high efficiency” and has created 11 products covering human blood albumin, human immunoglobulin and coagulation factors.

Dongtai Haorui Biotechnology Co., Ltd., established on 2016-07-01, Business scope includes biotechnology research and development,Stevia Takeover,food additives(steviol glycoside),feed ingredients(stevia residue),feed(roughage)Production,Sales,Stevia conversion(Glucosyl steviol glycoside)Production,Sales,bio organic fertilizer(Stevia slag organic fertilizer)Production(No chemical process),Sales,Biogas power generation(without biogas storage),PV,food(Salt limit for retail sales),daily necessities(In addition to electric tricycle),Gardening Product Sales,Self-operated and agent import and export business of various commodities and technologies(Except for goods and technologies restricted by the state or prohibited from import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Crop Seed Management(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Non-Major Crop Seed Production;sugar crop cultivation;Crop Cultivation Services;Agricultural Science Research and Experimental Development(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)